Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva
Year: 2004
Type: conference-abstract
Source: Journal of Clinical Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: gemcitabine, paclitaxel, metastatic breast cancer, first-line therapy, overall survival, combination chemotherapy, anthracycline-pretreated patients, time to progression, progression-free survival, objective response rate, quality of life, treatment toxicity, hazard ratio, interim analysis
Open Access status: closed
OpenAlex ID: W2376751074
